Bayer Intellectual Property Gmbh

Bayer Animal Health Gmbh

Bayer Aktiengesellschaft

Bayer Aktiengellschaft

Hermann Wehlmann

Jörn Kalinowski

Alfred Pühler

Patrick Schwientek

Klaus Selber

Winfried Rosen

Udo Wehmeier

Albert Abraham

Christian Weiss

Andrea Eicker

Heiner Apeler

Marc Munnes

Andreas Klein

Romina G Schauer

Elisabeth Feldhues

Rudolf H Hanko

Hanno Wild

Jurgen Beunink

Michael Dorschug

Bernhard Weingärtner

Bernhard Weingaertner

Hans-Dietrich Horlein

Romina Schauer

The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.

Immunostimulatory plasmids

The present invention describes the DNA-sequence of the wild type genome as well as all genetic modifications which were introduced into the wild type&#x2014;and further developed strains, based thereon. Thereby the first genotypic characterization of the developed strains, including the latest production strain, has been accomplished, accounting for the major part of the invention. Furthermore, on the basis of the determined DNA-sequences, potential genes were identified and account, combined with their functional annotation, for another part of the invention. In particular, the gene- and DNA-sequences, as well as protein-sequences derived there out, contribute to the invention which were affected by mutagenic modifications throughout the strain development process, potentially contributing to the increased production yield.

Genomics of actinoplanes utahensis

The present invention is directed to an innate DNA sequence within the complete genome sequence ofsp. SE50/110 which resembles the structure of an actinomycete integrative and conjugative element (AICE). Related AICEs were used for establishing genetic manipulation tools for other bacteria in the past. In this document, we describe the unique features of the specific AICE found insp. SE50/110 which are clearly distinct from any other known AICE as a whole, but share minor parts with varying sequence similarity with other characterized AICEs from other species.

[object Object]

The present invention is directed to an innate DNA sequence within the complete genome sequence ofsp. SE50/110 which resembles the structure of an actinomycete integrative and conjugative element (AICE). Related AICEs were used for establishing genetic manipulation tools for other bacteria in the past. In this document, we describe the unique features of the specific AICE found insp. SE50/110 which are clearly distinct from any other known AICE as a whole, but share minor parts with varying sequence similarity with other characterized AiCEs from other species.

The present invention relates to the construction and use of expression plasmids in the manufacture of recombinant interleukin-4 (IL-4) and interleukin-4 muteins.

Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins

hIL-4 mutant proteins used as antagonists or partial agonists of human

Growing community of inventors

Wuppertal, Germany

Hermann Wehlmann